Speakers

Expand/Collapse

Adrian Ortiz
Principal Scientist
Amgen Inc.

Adrian Ortiz received his B.S. in chemistry from the University of Arizona in 2004 where he performed research under the guidance of Professor Dominic V. McGrath. He then joined the group of Professor K.C. Nicolaou at the Scripps Research Institute in San Diego, CA where he studied the total synthesis of natural products. After completion of his Ph.D. in 2009, he joined the process group of Bristol-Myers Squibb and in 2019 he joined Amgen in Thousand Oaks, CA where he is currently Head of Pre-Pivotal Drug Substance Technologies and Biocatalysis.

Day One

Wednesday November 3, 2021

1:00 pm | Nitroreductase: Current Successes and Challenges at Amgen

Day Two

Thursday November 4, 2021

9:00 am | Panel: Biocatalysis for a Sustainable Pharma Future

Andreas Bommarius
Professor
Georgia Tech Research Institute

Day One

Wednesday November 3, 2021

9:30 am | Relevance of process modeling to biocatalysis at pilot scale

Day Two

Thursday November 4, 2021

9:00 am | Panel: Biocatalysis for a Sustainable Pharma Future

Andreas Liese
Professor, Head of Institute of Technical Biocatalysis
Hamburg University of Technology

Day Two

Thursday November 4, 2021

3:00 pm | Bioprocess Intensification by Non-Conventional Reaction Conditions

Beate Mueller-Tiemann
Vice President - iCMC New Products Program & Pharmaceutics Development Platform
Sanofi

Beate Mueller-Tiemann is currently Head of MSAT for General Medicines and Small Molecules at Sanofi. She is responsible for Sanofi’s product portfolio with an end-to-end responsibility (Drug Substance and Drug Product). Within her scope are various modalities and technologies, most prominently microbial Biotechnology for the production of Biologics as well as classical organic chemistry. Prior to this role Beate was responsible for Sanofi’s Synthetic Molecule CMC Development Platform and CMC Project Management. Beate also lead Technology & Innovation Strategy within Sanofi’s Biologics Platform.  Previously Beate held the role of Vice President Cell and Protein Sciences within Global Biologics Research at Bayer. In her more than 20 years’ experience in pharmaceutical R&D, she focused on protein science, with various roles in small molecule and biologics drug discovery. She started her career at Sandoz, Basel, Switzerland in Molecular Neurology Research, she moved into Molecular Oncology at Bayer Corporation in West Haven, Connecticut, USA, subsequently joined Schering AG in Berlin, Germany, focusing on High Throughput Technologies in Protein Sciences and Crystallography, before she moved to Bayer’s Research Center in Wuppertal, Germany, establishing and leading the Biologics Research Organization. Beate holds a Ph.D. in Biochemistry, Molecular Biology and Cell Biology from the University of Hamburg, Germany, and a Maîtrise de Biochimie of the University of Montpellier, France. 

Bettina Bommarius
Senior Research Scientist
Georgia Institute of Technology

Bettina Bommarius received her Ph.D. at the University of Duesseldorf, Germany, in 1997. Since then she has worked with several institutions, both academic as well as industrial, initially in Germany and since 2000 in the United States, to develop new protein functions and characterize proteins for either industrial purposes or within a disease background. Her expertise is within biocatalysis, protein development, bacterial pathogenicity and protein biophysics. She has joined Georgia Tech in 2012 as a research scientist and since 2016 manages the newly founded Biopolymer Characterization Core while still pursuing her research interests and industry partner projects as a Senior Research Scientist.

Day Two

Thursday November 4, 2021

2:30 pm | Process Developments Using Oxidoreductases

Chihui An
Associate Principal Scientist
Merck & Co

Chihui An completed his PhD in Chemistry at University of Pennsylvania where he completed the total synthesis of Irciniastatin B and it’s analogues to probe the molecule’s biological activity. Afterwards, Chihui was an NIH Ruth Kirchstein Postdoctoral fellow where he utilized protein engineering to reprogram Sortase A to modify disease associated proteins. In 2016, he joined Merck as a member of the Biocatalysis group and is currently an Associate Principal Scientist in Process Chemistry.

Day One

Wednesday November 3, 2021

3:00 pm | Biocatalytic Toolbox for Site-Selective Insulin Modification

David H Thompson
Professor - Organic Chemistry
Purdue University

Day Two

Thursday November 4, 2021

2:00 pm | Development of a Fast Organic Extraction-Precipitation Method for Enhanced Purification of Functional Elastin-like Polypeptides

Deeptak Verma
Senior Scientist
Merck

Day One

Wednesday November 3, 2021

3:30 pm | Deep Dive into Machine Learning Models For Directed- Evolution Of Enzymes

Doug Fuerst
Director - Technology Development & Synthetic Biochemistry Leader
GlaxoSmithKline

Doug Fuerst is currently Head of Synthetic Biochemistry at GlaxoSmithKline leading enzyme engineering efforts for biocatalysis.  Doug obtained his PhD in natural product total synthesis from Yale University, followed by postdoctoral research at Harvard University studying asymmetric catalysis.  Doug joined GSK in the Chemical Development department working on the discovery and development of large scale chemical processes with an emphasis on biocatalysis.   

Day Two

Thursday November 4, 2021

10:00 am | Accelerating The Adoption of Biocatalysis In the Pharmaceutical Industry

Francesco Falcioni
R&D leader in applied biocatalysis
AstraZeneca

Day Two

Thursday November 4, 2021

12:30 pm | Efficient BVMO-Catalyzed Enantioselective Sulfoxidation for API Production: From Assay Miniaturization to Rationally Guided Engineering

Hao Yang
Senior Scientist
Merck

Day Two

Thursday November 4, 2021

3:30 pm | Development of Novel Enzymatic Cascade in Molnupiravir Synthesis

Jacob Forstater
Associate Principal Scientist
Merck & Co

Jacob earned his Ph.D. in Physics from UNC-Chapel Hill, where he investigated protein self-assembly and protein-surface interactions. Before joining Merck in 2016, Jacob was a postdoctoral fellow at Columbia University, where he developed key nucleotide modifications and algorithms for a nanopore-based next-generation sequencing by synthesis technology.  Jacob is currently an Associate Principal Scientist in the Enabling Technologies group within Merck’s Small Molecule PR&D department, based in Rahway, NJ, where he leads the development and implementation of enzyme immobilization for biocatalytic processes.

Day Two

Thursday November 4, 2021

11:30 am | A Sustainable Biocatalytic Process for Manufacturing a Key API Starting Material

Jean Christophe Lec
Research and Development Scientist
Arkema

Day One

Wednesday November 3, 2021

9:00 am | Biocatalysis for Commodity and Speciality Chemistry

Jennifer Littlechild
Professor - Biological Chemistry & Director - Exeter Biocatalysis Centre Biological Chemistry
University of Exeter

Prof. Jennifer Littlechild is Professor of Biological Chemistry and has established the Henry Wellcome Centre for Biocatalysis at Exeter University in 2003. She carried out her PhD in Biophysics at Kings College, London University followed by a postdoctoral fellowship at Princeton University, USA. This was followed by a Max-Planck position in Berlin Germany before she returned to the UK to Bristol University and then to Exeter University in 1991. Her research studies involve the structural and mechanistic characterisation of a range of enzymes from thermophilic bacteria and Archaea that have industrial applications. She has published over 200 publications in refereed high impact journals and presented her research work internationally. She has coordinated the EU project THERMOGENE and was a partner in a consortium grant HOTZYME and currently RADICLEZ. A ERA-CoBiotech project HOTSOLUTE started in 2018 and an ERA-FOCS project THERMOK in 2021. In the UK she is funded from BBSRC, EPSRC, DEFRA and Innovate UK. These grants involve both large industrial companies and SME enterprises. She has supervised over 40 PhD students and acts as external examiner for other PhD and Masters students in the UK and Internationally. She is the UK representative and vice chair of the European Society of Applied Biocatalysis. 

Day Two

Thursday November 4, 2021

12:00 pm | Novel Thermophilic Biocatalysts with Applications for Industrial Biotechnology

Mary Andorfer
Postdoctoral Researcher
Massachusetts Institute of Technology

Mary Andorfer completed her PhD in chemistry in 2017 in the lab of Prof. Jared Lewis at The University of Chicago. Her thesis work focused on engineering flavin-dependent halogenases for use as biocatalysts. She is currently an NIH postdoctoral fellow in the lab of Prof. Catherine Drennan at MIT where she studies oxygen-sensitive enzymes within the glycyl radical enzyme superfamily using cryo-electron microscopy and other biophysical techniques.

Paul Race
Professor - Biological Chemistry
University of Bristol

Paul Race is Professor of Biological Chemistry in the School of Biochemistry, University of Bristol (UoB). He is a founding Director of the Bristol BioDesign Institute (BBI) and is Bristol lead for the EPSRC funded UK Innovation and Knowledge Centre (IKC) in synthetic biology (SynbiCITE). From 2014-2018 PRR served as Co-Director of the >£14M BBSRC/EPSRC funded Bristol Centre for Synthetic Biology Research (BrisSynBio). He vacated this role in early 2018 to lead the >£2.7M EPSRC funded ‘Manufacturing Immortality’ project, which aims to develop bio-hybrid living materials. Race’s research focuses on the exploitation and manipulation of enzyme complexes, pathways and networks, en route to the development of new bioactive molecules, drug leads and biocatalysts. This activity is underpinned by fundamental studies of natural systems performed using an inherently multi-disciplinary approach.

Day One

Wednesday November 3, 2021

11:30 am | Microbial lysyl oxidases: New Biocatalytic Tools for Chemical Biology, Materials Science And Beyond

Day Two

Thursday November 4, 2021

9:00 am | Panel: Biocatalysis for a Sustainable Pharma Future

Ryan Phelan
Senior Scientist - Biocatalysis, Process Chem & Catalysis Group
AbbVie

Ryan Phelan is a Senior Scientist at AbbVie in the Center of Catalysis (Process Chemistry) focused on integrating biocatalytic transformations in the synthesis of complex APIs. Prior to joining AbbVie in the Fall of 2016 Ryan performed his postdoctoral studies at the University of California, Berkeley with Prof. Jay Keasling using protein and metabolic engineering techniques to develop sustainable routes to biofuels and biopolymers. He obtained his Ph.D. at Johns Hopkins University, under the guidance of Prof. Craig Townsend, applying organic synthesis to elucidate how microbes synthesize complex beta-lactam antibiotics.

Day One

Wednesday November 3, 2021

11:00 am | Modifying Reaction Conditions to Enhancing Reactions and Avoiding Enzyme Engineering

Sherif Elshahawi
Assistant Professor
Chapman University

Dr. Sherif Elshahawi is an Assistant Professor at the Department of Biomedical and Pharmaceutical Sciences at Chapman University School of Pharmacy (CUSP). He received his BPharm in 2000, MSc in 2006 from the University of Mississippi and PhD in 2012 from Oregon Health & Science University. He did his Postdoctoral training at the University of Kentucky in Professor Jon Thorson’s lab. His research interests include natural products discovery and biosynthesis, biocatalysis, drug development and protein engineering.

Day One

Wednesday November 3, 2021

1:30 pm | Late-Stage Chemoenzymatic Modifications of an FDAApproved Antibiotic

Thierry Schlama
Team Leader - Biocatalysis & Protein Engineering & Global Scientific Partnering Network Leader & Biocatalysis Platform Leader
Novartis

24 years experiences in Process research and technology development. Passionate of enzyme catalysis.

Day Two

Thursday November 4, 2021

9:30 am | From Early Phase To Full Scale Manufacturing, An Overview Of Biocatalysis At Novartis Pharma

Wai Ling Cheung-Lee
Senior Scientist
Merck

Day Two

Thursday November 4, 2021

11:00 am | Enzyme Engineering to Enable an Efficient & Sustainable Biocatalytic Process